PT858804E - Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose - Google Patents

Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose

Info

Publication number
PT858804E
PT858804E PT98101081T PT98101081T PT858804E PT 858804 E PT858804 E PT 858804E PT 98101081 T PT98101081 T PT 98101081T PT 98101081 T PT98101081 T PT 98101081T PT 858804 E PT858804 E PT 858804E
Authority
PT
Portugal
Prior art keywords
treatment
crisposporidios
rifaximine
diarrhea
drug
Prior art date
Application number
PT98101081T
Other languages
English (en)
Inventor
Antonella Ferrieri
Patrizio Ferrari
Pietro Caramello
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of PT858804E publication Critical patent/PT858804E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PT98101081T 1997-02-14 1998-01-22 Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose PT858804E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (1)

Publication Number Publication Date
PT858804E true PT858804E (pt) 2002-10-31

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98101081T PT858804E (pt) 1997-02-14 1998-01-22 Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose

Country Status (12)

Country Link
US (1) US5886002A (pt)
EP (1) EP0858804B1 (pt)
JP (1) JP4848083B2 (pt)
KR (1) KR100436243B1 (pt)
CN (1) CN1115146C (pt)
AT (1) ATE218342T1 (pt)
DE (1) DE69805672T2 (pt)
DK (1) DK0858804T3 (pt)
ES (1) ES2178048T3 (pt)
HU (1) HU224592B1 (pt)
IT (1) IT1290679B1 (pt)
PT (1) PT858804E (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
EP1620420A2 (en) * 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Substituted carboxylic acids
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
HUE025306T2 (hu) * 2006-08-02 2016-01-28 Salix Pharmaceuticals Inc Sugárterápia által okozott bélgyulladás kezelésére irányuló módszer
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
CN102164599B (zh) 2008-09-26 2014-07-23 Aska制药株式会社 预防和/或治疗功能性胃肠障碍的药剂
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (en) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011110930A2 (en) * 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
KR20140029356A (ko) 2010-09-13 2014-03-10 시플라 리미티드 약학 조성물
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
EP3160467B1 (en) * 2014-06-30 2021-03-10 Salix Pharmaceuticals, Inc. Combination comprising rifaximin and cyclosporine for use in the treatment of bowel diseases
WO2016138118A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals
CA2988930A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
AU2017343886B2 (en) 2016-10-14 2023-07-06 Cipla Limited Pharmaceutical compositions comprising rifaximin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
CN1115146C (zh) 2003-07-23
KR19980071348A (ko) 1998-10-26
KR100436243B1 (ko) 2004-08-25
ITBO970064A1 (it) 1998-08-14
HUP9800115A3 (en) 2000-04-28
ITBO970064A0 (it) 1997-02-14
EP0858804B1 (en) 2002-06-05
ES2178048T3 (es) 2002-12-16
ATE218342T1 (de) 2002-06-15
DE69805672D1 (de) 2002-07-11
IT1290679B1 (it) 1998-12-10
US5886002A (en) 1999-03-23
DE69805672T2 (de) 2003-01-23
DK0858804T3 (da) 2002-07-08
HU9800115D0 (en) 1998-03-30
CN1214244A (zh) 1999-04-21
JP4848083B2 (ja) 2011-12-28
JPH10226645A (ja) 1998-08-25
HU224592B1 (hu) 2005-11-28
EP0858804A1 (en) 1998-08-19
HUP9800115A1 (hu) 1999-06-28

Similar Documents

Publication Publication Date Title
PT858804E (pt) Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE60042153D1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
BR0107333A (pt) Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
DE69830503D1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
FI954131A (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
GB0111186D0 (en) Novel compounds
ES2195397T3 (es) Quinazolin-2,4-dionas sustituidas en posicion 7 utiles como agentes antibacterianos.
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
YU13301A (sh) Muskarinski agonisti i antagonisti
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
ID29790A (id) PENGGUNAAN IMIDAZO(1,5-a)-PIRIDO(3,2-e)-PIRAZINON SEBAGAI OBAT
PT1463735E (pt) Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
ES2174573T3 (es) Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
AP9801307A0 (en) Use of 3-amino-4-hydroxbenzoic acid for treatment of retroviral infections.
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler